MedTrace Logo

A Multicenter, Double-blind, Parallel Phase III Study

NCT02352584 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1299

Last updated 2015-10-20

No results posted yet for this study

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III

Conditions

Interventions

BIOLOGICAL

GC3110A(Quadrivalent)

GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1

BIOLOGICAL

GC Flu(Trivalent)

GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1

BIOLOGICAL

GC3110A(Trivalent)

GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1

Sponsors & Collaborators

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • Lee Jin Su, M.D · Inha University Hospital

  • Choi Won Seck, M.D · Korea University Ansan Hospital

  • Lee Ja Cob · Hallym Univ. Medical Center

  • Woo Heong Jung · Hallym Univ. Medical Center

  • Wi Sung Heon · St Vincent's Hospital

  • Jeong Suk In · Chonnam Natinal University Hospital

  • Kim Sin Woo · Kyungpook National University Hospital

  • Kim Tae Hyung · Soon Chun Hyang Univ. Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2014-12-31
Completion
2015-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02352584 on ClinicalTrials.gov